Citigroup Inc Aura Biosciences, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Citigroup Inc holds 33,900 shares of AURA stock, worth $277,980. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,900

Previous 10,412 225.59%

Holding current value

$277,980

Previous $78,000 287.18%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$6.9 - $10.36 $162,067 - $243,335	23,488 Added 225.59%	33,900 $302,000
Q2 2024 Aug 12, 2024	BUY	$6.81 - $7.89 $25,380 - $29,406	3,727 Added 55.75%	10,412 $78,000
Q1 2024 May 10, 2024	BUY	$7.09 - $9.24 $18,923 - $24,661	2,669 Added 66.46%	6,685 $52,000
Q4 2023 Feb 09, 2024	SELL	$7.02 - $11.98 $718,918 - $1.23 Million	-102,410 Reduced 96.23%	4,016 $35,000
Q3 2023 Nov 09, 2023	SELL	$8.97 - $12.38 $377,367 - $520,826	-42,070 Reduced 28.33%	106,426 $954,000
Q2 2023 Aug 10, 2023	SELL	$8.51 - $13.33 $3.13 Million - $4.9 Million	-367,546 Reduced 71.22%	148,496 $1.83 Million
Q1 2023 May 11, 2023	BUY	$8.88 - $12.11 $3.29 Million - $4.48 Million	370,338 Added 254.17%	516,042 $4.79 Million
Q4 2022 Feb 09, 2023	SELL	$9.86 - $14.59 $39,794 - $58,885	-4,036 Reduced 2.7%	145,704 $1.53 Million
Q3 2022 Nov 10, 2022	BUY	$13.1 - $20.34 $347,831 - $540,067	26,552 Added 21.55%	149,740 $2.71 Million
Q2 2022 Aug 10, 2022	BUY	$12.37 - $21.86 $1.52 Million - $2.69 Million	122,969 Added 56150.23%	123,188 $1.75 Million
Q1 2022 May 12, 2022	SELL	$15.94 - $23.34 $25,280 - $37,017	-1,586 Reduced 87.87%	219 $5,000
Q4 2021 Feb 10, 2022	BUY	$14.76 - $24.89 $26,641 - $44,926	1,805 New	1,805 $31,000

Others Institutions Holding AURA

# of Institutions

Shares Held

37.6M

Call Options Held

122K

Put Options Held

38.5K

View Full List

About Aura Biosciences, Inc.

Ticker AURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,273,600
Market Cap $240M
Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...

More about AURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account